Comment
Author: Admin | 2025-04-28
Abilify is a drug owned by Otsuka Pharmaceutical Co Ltd. It is protected by 25 US drug patents filed from 2013 to 2016. Out of these, 2 drug patents are active and 23 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 02, 2027. Details of Abilify's patents and their expiration are given in the table below. Drug Patent Number Drug Patent Title Drug Patent Expiry Status These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. US9359302 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof Sep, 2022 (2 years ago) Expired US8642760 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof Sep, 2022 (2 years ago) Expired US8580796 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof Sep, 2022 (2 years ago) Expired These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). US8759350 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders Mar, 2027 (2 years from now) Active US9125939 Carbostyril derivatives and mood stabilizers for treating mood disorders Jul, 2026 (1 year, 4 months from now) Active US7115587 (Pediatric) Aripiprazole complex formulation and method Jan, 2025 (a month ago) Expired US7550445 (Pediatric) Aripiprazole complex formulation and method Jan, 2025 (a month ago) Expired US8017615 (Pediatric) Low hygroscopic aripiprazole drug substance and processes for the preparation thereof Dec, 2024 (2 months ago) Expired US7115587 Aripiprazole complex formulation and method Jul, 2024 (7 months ago) Expired US7550445 Aripiprazole complex formulation and method Jul, 2024 (7 months ago) Expired US8017615 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof Jun, 2024 (8 months ago) Expired US9387182 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders Dec, 2023 (1 year, 2 months ago) Expired US8642760 (Pediatric) Low hygroscopic aripiprazole drug substance and processes for the preparation thereof Mar, 2023 (1 year, 11 months ago) Expired US8580796 (Pediatric) Low hygroscopic aripiprazole drug substance and processes for the preparation thereof Mar, 2023 (1 year, 11 months ago) Expired US6977257 (Pediatric) Aripiprazole oral solution Oct, 2022 (2 years ago) Expired US8642600 (Pediatric) Method of treating autism Jul, 2022 (2 years ago) Expired US6977257 Aripiprazole oral solution Apr, 2022 (2 years ago) Expired US8642600 Method of treating autism Jan, 2022 (3 years ago) Expired US7053092 5-HT1a receptor subtype agonist Jan, 2022 (3 years ago) Expired US9089567 Method of treating cognitive impairments and schizophrenias Jan, 2022 (3 years ago) Expired US8518421 (Pediatric) Flashmelt oral dosage formulation Jul, 2021 (3 years ago) Expired US8518421 Flashmelt oral dosage formulation Jan, 2021 (4 years ago) Expired US9358207 Flashmelt oral dosage formulation Apr, 2020 (4 years ago) Expired US5006528 (Pediatric) Carbostyril derivatives Apr, 2015 (9 years ago) Expired US5006528 Carbostyril derivatives Oct, 2014 (10 years ago) Expired A patent's expiry date may change depending upon legal activities going on that patent. Critical
Add Comment